CORPORATE - 07-11-2016

Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment

FDA has accepted for review a BLA for a human anti-rabies immunoglobulin (IgG) therapy

read more 

CORPORATE - 13-09-2016

Kedrion Biopharma set for strong presence at 2016 IgNS Meeting

Kedrion Biopharma will be a bronze sponsor at the Immunoglobulin National Society (IgNS) 2016 5th National Conference

read more 

CORPORATE - 01-09-2016

Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin

Kamada and Kedrion, collaborators on development and commercialization of post-exposure treatment for suspected rabies, announced today the filing of a BLA with the FDA.

read more 

CORPORATE - 22-08-2016

Kedrion Biopharma to attend 14th International Symposium of GBS/CIPD Foundation

Kedrion Biopharma will be a Silver Sponsor at the 14th International Symposium of GBS/CIPD Foundation

read more 

Pages